Steffen Naegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Steffen Naegel has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Mark Obermann
Department of Neurology, Klinikum Weser-Egge, Höxter, Germany
8 shared publicationsDagny Holle
Department of Neurology, Westgerman Headache Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany
7 shared publications- Christoph Kleinschnitz
Department of Neurology, University Hospital Essen, Essen, Germany
6 shared publications - Dagny Holle
Department of Neurology, University of Duisburg-Essen, Essen, Germany
6 shared publications - Hans-Christoph Diener
Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Faculty of Medicine, University Duisburg-Essen, Essen, Germany
6 shared publications - Charly Gaul
Medical Faculty, University of Duisburg-Essen, Essen, Germany
5 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 228
In the heat of the moment: prevalence and clinical characteristics of headache associated with sexual activity (head HEATS study)
Background: Headache associated with sexual activity (HAS) is an uncommon and understudied primary headache disorder. Previous epidemiological studies have estimated a lifetime prevalence of approximately 1.0–1.6%, although the true prevalence remains uncertain because symptoms related to sexual activity may be underreported. Objective: This study aimed to assess the prevalence and clinical characteristics of HAS and its co-occurrence with other primary headache disorders in a university-based cohort. Methods: A cross-sectional questionnaire study was conducted among students and employees at Martin- Luther-University Halle-Wittenberg, Germany. Of 1213 distributed questionnaires, 606 with complete age and sex information were included in the final analysis. Continuous variables were assessed for normality and compared using non-parametric methods when appropriate. Categorical variables were compared using two-sided Fisher’s exact tests. Associations with HAS were explored using parsimonious Firth penalized logistic regression models. Results: Twenty-three of 606 participants reported HAS, corresponding to a lifetime prevalence of 3.8% (95% CI, 2.6–5.6%). Participants with HAS were older than those without HAS (median [IQR], 25 [21–34.5] vs. 21 [19–26] years; p = 0.005). Although 82.6% of participants with HAS were female, the proportion did not differ significantly between groups (82.6% vs. 68.6%; p = 0.175). Among participants with available timing data, headache occurred during sexual arousal or the buildup to orgasm in 57.9% and at orgasm in 42.1%. Clinical characteristics were heterogeneous with respect to pain quality and localization, and symptoms compatible with migraine aura were reported by 34.7%. Migraine and tension-type headache were not significantly associated with HAS. In age- and sex-adjusted Firth penalized logistic regression, primary exercise headache was associated with higher odds of HAS (aOR 4.06, 95% CI 1.41–11.72; p = 0.010). Conclusions: In this university-based questionnaire study, 3.8% of participants reported symptoms compatible with HAS. The clinical presentation was heterogeneous, and primary exercise headache was associated with higher odds of HAS after adjustment for age and sex. Given the small number of HAS cases, questionnaire-based case ascertainment, and potential selection and response bias, these findings should be considered exploratory and should not be interpreted as population-representative prevalence estimates. Larger studies using clinician-confirmed diagnoses are needed to validate these findings.
- 29 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 228
Open AccessIn the heat of the moment: prevalence and clinical characteristics of headache associated with sexual activity (head HEATS study)
Background: Headache associated with sexual activity (HAS) is an uncommon and understudied primary headache disorder. Previous epidemiological studies have estimated a lifetime prevalence of approximately 1.0–1.6%, although the true prevalence remains uncertain because symptoms related to sexual activity may be underreported. Objective: This study aimed to assess the prevalence and clinical characteristics of HAS and its co-occurrence with other primary headache disorders in a university-based cohort. Methods: A cross-sectional questionnaire study was conducted among students and employees at Martin- Luther-University Halle-Wittenberg, Germany. Of 1213 distributed questionnaires, 606 with complete age and sex information were included in the final analysis. Continuous variables were assessed for normality and compared using non-parametric methods when appropriate. Categorical variables were compared using two-sided Fisher’s exact tests. Associations with HAS were explored using parsimonious Firth penalized logistic regression models. Results: Twenty-three of 606 participants reported HAS, corresponding to a lifetime prevalence of 3.8% (95% CI, 2.6–5.6%). Participants with HAS were older than those without HAS (median [IQR], 25 [21–34.5] vs. 21 [19–26] years; p = 0.005). Although 82.6% of participants with HAS were female, the proportion did not differ significantly between groups (82.6% vs. 68.6%; p = 0.175). Among participants with available timing data, headache occurred during sexual arousal or the buildup to orgasm in 57.9% and at orgasm in 42.1%. Clinical characteristics were heterogeneous with respect to pain quality and localization, and symptoms compatible with migraine aura were reported by 34.7%. Migraine and tension-type headache were not significantly associated with HAS. In age- and sex-adjusted Firth penalized logistic regression, primary exercise headache was associated with higher odds of HAS (aOR 4.06, 95% CI 1.41–11.72; p = 0.010). Conclusions: In this university-based questionnaire study, 3.8% of participants reported symptoms compatible with HAS. The clinical presentation was heterogeneous, and primary exercise headache was associated with higher odds of HAS after adjustment for age and sex. Given the small number of HAS cases, questionnaire-based case ascertainment, and potential selection and response bias, these findings should be considered exploratory and should not be interpreted as population-representative prevalence estimates. Larger studies using clinician-confirmed diagnoses are needed to validate these findings.
- Open Access
- 23 March 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (3) , e70579
Quantitative Whole‐Body Muscle MRI in Adults With Spinal Muscular Atrophy–A Sensitive Tool for Long‐Time Evaluation of Disease Progression
Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by progressive muscle weakness due to SMN protein deficiency. While effective therapies exist, their impact on slowly progressive adult SMA patients remains unclear. Reliable biomarkers for monitoring disease progression and treatment response are urgently needed. This pilot study evaluated the utility of longitudinal quantitative muscle MRI (qMRI) to monitor disease progression in adult SMA patients treated with nusinersen over an extended period. Methods: Nine adult patients with genetically confirmed 5q‐SMA underwent whole‐body muscle MRI and clinical assessment, including the Hammersmith Functional Motor Scale‐Expanded (HFMS‐EXP), Revised Upper Limb Module (RULM), and 6 min walk test (6MWT). Muscular fat fraction (mFF) was quantified in 20 muscles over a median follow‐up of 54 months. Results: Baseline mFF correlated strongly with clinical measures (HFMS‐EXP: r = −0.90, p = 0.001; 6MWT: r = −0.96, p < 0.001), but not with age at onset or age at MRI. Over the observation period, a significant increase in mFF was detected (averaged annual increase of all studied muscles: 0.47%, p = 0.011), accentuated in the lower leg muscles. In contrast, clinical measures showed no consistent change. Consequently, no significant correlations were found between changes in mFF and clinical scores. Conclusions: This study provides the longest reported longitudinal qMRI assessment in adult SMA patients treated with nusinersen, demonstrating that mFF progressively increases despite stable clinical scores. The results suggest that qMRI may be a sensitive and objective biomarker for detecting subtle disease progression in adult SMA, potentially surpassing clinical measures.
- 23 March 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (3) , e70579
Open AccessQuantitative Whole‐Body Muscle MRI in Adults With Spinal Muscular Atrophy–A Sensitive Tool for Long‐Time Evaluation of Disease Progression
Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by progressive muscle weakness due to SMN protein deficiency. While effective therapies exist, their impact on slowly progressive adult SMA patients remains unclear. Reliable biomarkers for monitoring disease progression and treatment response are urgently needed. This pilot study evaluated the utility of longitudinal quantitative muscle MRI (qMRI) to monitor disease progression in adult SMA patients treated with nusinersen over an extended period. Methods: Nine adult patients with genetically confirmed 5q‐SMA underwent whole‐body muscle MRI and clinical assessment, including the Hammersmith Functional Motor Scale‐Expanded (HFMS‐EXP), Revised Upper Limb Module (RULM), and 6 min walk test (6MWT). Muscular fat fraction (mFF) was quantified in 20 muscles over a median follow‐up of 54 months. Results: Baseline mFF correlated strongly with clinical measures (HFMS‐EXP: r = −0.90, p = 0.001; 6MWT: r = −0.96, p < 0.001), but not with age at onset or age at MRI. Over the observation period, a significant increase in mFF was detected (averaged annual increase of all studied muscles: 0.47%, p = 0.011), accentuated in the lower leg muscles. In contrast, clinical measures showed no consistent change. Consequently, no significant correlations were found between changes in mFF and clinical scores. Conclusions: This study provides the longest reported longitudinal qMRI assessment in adult SMA patients treated with nusinersen, demonstrating that mFF progressively increases despite stable clinical scores. The results suggest that qMRI may be a sensitive and objective biomarker for detecting subtle disease progression in adult SMA, potentially surpassing clinical measures.
- Open Access
- 8 January 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70481
Letter to the Editor: Reaffirming Caution—The Unacceptable Vasoconstrictive Risk of CGRP ‐Related Therapies in Moyamoya Angiopathy
- 8 January 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70481
Open AccessLetter to the Editor: Reaffirming Caution—The Unacceptable Vasoconstrictive Risk of CGRP ‐Related Therapies in Moyamoya Angiopathy
- Open Access
- 19 May 2025
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 51 (3) , e70019
Alpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle
Aims: Diagnosis of inclusion body myositis (IBM) is difficult and currently based on a combination of clinical and (immuno)histological findings. Biomarkers facilitating the diagnostic process are needed. Alpha‐synuclein (αSN) aggregates are a known histological feature of IBM, but there is a lack of information on their diagnostic relevance. Furthermore, serum αSN concentrations in IBM have not been investigated.Methods: Immunohistochemical staining for αSN was performed on 63 biopsies (19 IBM, 21 other inflammatory myopathies, 20 other myopathies and 3 healthy controls), and αSN reactive fibres were quantified. The serum concentration of αSN was determined by ELISA in 156 serum samples (11 IBM, 25 other inflammatory myopathies, 53 hereditary myopathies, 30 mitochondriopathies and 37 healthy controls).Results: The proportion of fibres with αSN immunoreactivity was significantly higher in IBM compared to all groups (p < 0.001) and discriminated IBM against all other neuromuscular disorders with a sensitivity of 79% and a specificity of 85%, which further improved when only non‐regenerating fibres were examined. In serum, αSN concentrations in IBM were generally not different from healthy controls. However, serum concentrations were inversely correlated with disease duration (r = −0.62, p = 0.04) and positively correlated with the IBM functional rating scale (r = 0.74, p = 0.01). Consequently, stratification according to these clinical parameters showed significantly lower serum αSN concentrations in late‐stage, more severely affected patients.Conclusions: αSN reactivity may serve as an additional immunohistochemical marker for IBM diagnosis. Furthermore, this study indicates that αSN serum concentrations decrease with disease duration and clinical deterioration. Therefore, serum αSN may be provisionally considered a monitoring biomarker in IBM, pending further studies.
- 19 May 2025
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 51 (3) , e70019
Open AccessAlpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle
Aims: Diagnosis of inclusion body myositis (IBM) is difficult and currently based on a combination of clinical and (immuno)histological findings. Biomarkers facilitating the diagnostic process are needed. Alpha‐synuclein (αSN) aggregates are a known histological feature of IBM, but there is a lack of information on their diagnostic relevance. Furthermore, serum αSN concentrations in IBM have not been investigated.Methods: Immunohistochemical staining for αSN was performed on 63 biopsies (19 IBM, 21 other inflammatory myopathies, 20 other myopathies and 3 healthy controls), and αSN reactive fibres were quantified. The serum concentration of αSN was determined by ELISA in 156 serum samples (11 IBM, 25 other inflammatory myopathies, 53 hereditary myopathies, 30 mitochondriopathies and 37 healthy controls).Results: The proportion of fibres with αSN immunoreactivity was significantly higher in IBM compared to all groups (p < 0.001) and discriminated IBM against all other neuromuscular disorders with a sensitivity of 79% and a specificity of 85%, which further improved when only non‐regenerating fibres were examined. In serum, αSN concentrations in IBM were generally not different from healthy controls. However, serum concentrations were inversely correlated with disease duration (r = −0.62, p = 0.04) and positively correlated with the IBM functional rating scale (r = 0.74, p = 0.01). Consequently, stratification according to these clinical parameters showed significantly lower serum αSN concentrations in late‐stage, more severely affected patients.Conclusions: αSN reactivity may serve as an additional immunohistochemical marker for IBM diagnosis. Furthermore, this study indicates that αSN serum concentrations decrease with disease duration and clinical deterioration. Therefore, serum αSN may be provisionally considered a monitoring biomarker in IBM, pending further studies.
- Open Access
- 27 July 2024
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 124 (5) , 1663-1670
Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience
Background: Erenumab is a monoclonal antibody specifically targeting the CGRP-receptor. Several studies showed efficacy and safety in patients with migraine. Less is known regarding dosage increase, especially in a difficult to treat patients. The aim of the study is to evaluate the increased dosage under real world conditions with particular focus on 70 mg non-responders. Methods: In a retrospective analysis, patients treated in tertiary headache centers (Halle or Jena, Germany) receiving 70 mg erenumab for at least 3 months with a dosage increase to 140 mg were analyzed. Data were evaluated regarding headache days, intake of acute medication, previous prophylaxis, and medication overuse. Baseline and all treatment intervals were determined as three-month periods. Results: Datasets of 52 migraine patients (90.4% women) aged between 22 and 78 years (mean 50.4 years, SD 12.1 years) were analyzed. At baseline (mean headache-days 15.67 ± 6.37) 51.9% met criteria for chronic migraine and 56% were currently overusing acute medication. While therapy with 70 mg showed significant improvement in headache days and 50% response, further improvement was not achieved for therapy escalation to 140 mg. The same applies to the secondary endpoints and covers the entire study population as well as the subgroups of chronic and episodic migraine. The 50% response of the 70 mg non-responders for escalation was only 5.14%. Conclusions: In this difficult-to-treat patient cohort we reconfirmed the effectiveness of erenumab, but could not detect any additional benefit for a dosage escalation from 70 mg to 140 mg erenumab.
- 27 July 2024
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 124 (5) , 1663-1670
Open AccessErenumab escalation in migraine - double dose without additional benefit - a retrospective experience
Background: Erenumab is a monoclonal antibody specifically targeting the CGRP-receptor. Several studies showed efficacy and safety in patients with migraine. Less is known regarding dosage increase, especially in a difficult to treat patients. The aim of the study is to evaluate the increased dosage under real world conditions with particular focus on 70 mg non-responders. Methods: In a retrospective analysis, patients treated in tertiary headache centers (Halle or Jena, Germany) receiving 70 mg erenumab for at least 3 months with a dosage increase to 140 mg were analyzed. Data were evaluated regarding headache days, intake of acute medication, previous prophylaxis, and medication overuse. Baseline and all treatment intervals were determined as three-month periods. Results: Datasets of 52 migraine patients (90.4% women) aged between 22 and 78 years (mean 50.4 years, SD 12.1 years) were analyzed. At baseline (mean headache-days 15.67 ± 6.37) 51.9% met criteria for chronic migraine and 56% were currently overusing acute medication. While therapy with 70 mg showed significant improvement in headache days and 50% response, further improvement was not achieved for therapy escalation to 140 mg. The same applies to the secondary endpoints and covers the entire study population as well as the subgroups of chronic and episodic migraine. The 50% response of the 70 mg non-responders for escalation was only 5.14%. Conclusions: In this difficult-to-treat patient cohort we reconfirmed the effectiveness of erenumab, but could not detect any additional benefit for a dosage escalation from 70 mg to 140 mg erenumab.
- 18 July 2024
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 92 (07/08) , 298-303
Kopfschmerz bei Medikamentenübergebrauch
Zusammenfassung: Der Kopfschmerz durch Medikamentenübergebrauch (MOH) ist eine weltweit verbreitete und beeinträchtigende Erkrankung, die durch übermäßige Einnahme von Akuttherapie entsteht und die Lebensqualität erheblich beeinträchtigen kann und das obwohl z.B. einfache Informationen über Ursachen und Folgen der Erkrankung dazu beitragen können, den MOH zu verhindern oder zu beenden. In den letzten Jahren konnten viele neue Erkenntnisse zum Kopfschmerz durch Medikamentenübergebrauch generiert werden. Zudem haben sich die Diagnosekriterien und die Leitlinienempfehlungen umfassend gewandelt. Dieser Artikel bietet einen umfassenden Überblick über die Klinik, Definition/Klassifikation, Epidemiologie, Risikofaktoren, Pathophysiologie, Kontroversen, Prävention und Behandlung des MOH.
- 18 July 2024
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 92 (07/08) , 298-303
Kopfschmerz bei Medikamentenübergebrauch
Zusammenfassung: Der Kopfschmerz durch Medikamentenübergebrauch (MOH) ist eine weltweit verbreitete und beeinträchtigende Erkrankung, die durch übermäßige Einnahme von Akuttherapie entsteht und die Lebensqualität erheblich beeinträchtigen kann und das obwohl z.B. einfache Informationen über Ursachen und Folgen der Erkrankung dazu beitragen können, den MOH zu verhindern oder zu beenden. In den letzten Jahren konnten viele neue Erkenntnisse zum Kopfschmerz durch Medikamentenübergebrauch generiert werden. Zudem haben sich die Diagnosekriterien und die Leitlinienempfehlungen umfassend gewandelt. Dieser Artikel bietet einen umfassenden Überblick über die Klinik, Definition/Klassifikation, Epidemiologie, Risikofaktoren, Pathophysiologie, Kontroversen, Prävention und Behandlung des MOH.
- 16 March 2022
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 90 (03) , 121-134
Trigeminoautonome Kopfschmerzen
Im Vergleich zur Migräne und zum Kopfschmerz vom Spannungstyp sind trigeminoautonome Kopfschmerzen (TAK) zwar selten, aber die erhebliche Beeinträchtigung und die nicht unerhebliche Prävalenz [1] (z. B. Clusterkopfschmerz 0,1%) machen TAK zu wichtigen Diagnosen. Die korrekte Diagnosestellung erfolgt allerdings leider oft verzögert. Dieser Beitrag gibt einen Überblick über das diagnostische Vorgehen und die therapeutischen Möglichkeiten bei TAK. Compared with migraine and tension-type headache, trigeminal autonomic cephalgias (TAC) are rare, but the resulting significant impairment and the not irrelevant prevalence (e. g., cluster headache 0.1%) make TACs important diagnoses. Unfortunately, the correct diagnosis is often delayed. This article provides an overview of the diagnostic approach and therapeutic options in TACs. Publication Date: 16 March 2022 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 16 March 2022
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 90 (03) , 121-134
Trigeminoautonome Kopfschmerzen
Im Vergleich zur Migräne und zum Kopfschmerz vom Spannungstyp sind trigeminoautonome Kopfschmerzen (TAK) zwar selten, aber die erhebliche Beeinträchtigung und die nicht unerhebliche Prävalenz [1] (z. B. Clusterkopfschmerz 0,1%) machen TAK zu wichtigen Diagnosen. Die korrekte Diagnosestellung erfolgt allerdings leider oft verzögert. Dieser Beitrag gibt einen Überblick über das diagnostische Vorgehen und die therapeutischen Möglichkeiten bei TAK. Compared with migraine and tension-type headache, trigeminal autonomic cephalgias (TAC) are rare, but the resulting significant impairment and the not irrelevant prevalence (e. g., cluster headache 0.1%) make TACs important diagnoses. Unfortunately, the correct diagnosis is often delayed. This article provides an overview of the diagnostic approach and therapeutic options in TACs. Publication Date: 16 March 2022 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 12 October 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-10
Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study
Background: Persistent postural-perceptual dizziness (PPPD) is the most common functional vestibular disorder. A multisensory mismatch altered by psychological influences is considered to be an important pathophysiological mechanism. Increased cortical and subcortical excitability may play a role in the pathophysiology of PPPD. We hypothesized that decreased motion perception thresholds reflect one mechanism of the abnormal vestibular responsiveness in this disorder. We investigated the vestibular perception thresholds and the vestibular ocular reflex with a rotatory chair experiment to gain insights in the processing and adaption to vestibular provocation. Methods: In this cross-sectional study 26 female PPPD patients and 33 healthy female age matched controls (HC) were investigated sitting in a motorized rotary chair shielded regarding visual and acoustic stimuli. The chair was rotated for 20 minutes with slowly increasing velocity to a maximum of 72°/s. We functionally tested motion perception thresholds and vegetative responses to rotation as well as vestibular-ocular reflex thresholds. We additionally investigated several psychological comorbidities (i.e. depression, anxiety, somatosensory amplification) using validated scores. Conventional dizziness scores were obtained to quantify the experienced dizziness and impact on daily life. Results: PPPD patients showed a significant reduced vestibulo-perceptual threshold (PPPD: 10.9°/s vs. HC: 29.5°/s; pp=0.043). No significant difference was measured regarding nystagmus parameters between both groups. Conclusion: PPPD patients showed increased vegetative response as well as decreased vestibulo-perceptual thresholds which are related to disease duration. This is of interest as PPPD might be sustained by increased vestibular excitability leading to motion intolerance and induction of dizziness when exposed to movement.
- 12 October 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-10
Open AccessReduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study
Background: Persistent postural-perceptual dizziness (PPPD) is the most common functional vestibular disorder. A multisensory mismatch altered by psychological influences is considered to be an important pathophysiological mechanism. Increased cortical and subcortical excitability may play a role in the pathophysiology of PPPD. We hypothesized that decreased motion perception thresholds reflect one mechanism of the abnormal vestibular responsiveness in this disorder. We investigated the vestibular perception thresholds and the vestibular ocular reflex with a rotatory chair experiment to gain insights in the processing and adaption to vestibular provocation. Methods: In this cross-sectional study 26 female PPPD patients and 33 healthy female age matched controls (HC) were investigated sitting in a motorized rotary chair shielded regarding visual and acoustic stimuli. The chair was rotated for 20 minutes with slowly increasing velocity to a maximum of 72°/s. We functionally tested motion perception thresholds and vegetative responses to rotation as well as vestibular-ocular reflex thresholds. We additionally investigated several psychological comorbidities (i.e. depression, anxiety, somatosensory amplification) using validated scores. Conventional dizziness scores were obtained to quantify the experienced dizziness and impact on daily life. Results: PPPD patients showed a significant reduced vestibulo-perceptual threshold (PPPD: 10.9°/s vs. HC: 29.5°/s; pp=0.043). No significant difference was measured regarding nystagmus parameters between both groups. Conclusion: PPPD patients showed increased vegetative response as well as decreased vestibulo-perceptual thresholds which are related to disease duration. This is of interest as PPPD might be sustained by increased vestibular excitability leading to motion intolerance and induction of dizziness when exposed to movement.
- 4 October 2021
- Published by SAGE Publications in Cephalalgia
- Vol. 42 (4-5) , 335-344
No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study
Objective: To identify grey matter alterations in patients suffering new daily persistent headache to enrich the pathophysiological concept of this rare headache disorder characterised by a distinct, clearly remembered onset and its instant chronification. Method: Magnetic resonance-based voxel-based and surface-based morphometry was used to investigate 23 patients suffering from new daily persistent headache and 23 age- and gender-matched healthy controls with 1.5 Tesla MRI. Independent statistical analysis was performed at three sites using statistical parametric mapping, as well as FSL(FMRIB Software Library)-based approaches. Results: No grey matter changes were detected using this sophisticated and cross-checked method. Conclusion: The absence of structural brain changes in patients with new daily persistent headache contribute to the recent discussion regarding structural alterations in primary headache disorders in general and does not provide evidence for grey matter changes being associated with the pathophysiology of new daily persistent headache. Future research will have to determine the underlying pathophysiological mechanisms of this disorder.
- 4 October 2021
- Published by SAGE Publications in Cephalalgia
- Vol. 42 (4-5) , 335-344
No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study
Objective: To identify grey matter alterations in patients suffering new daily persistent headache to enrich the pathophysiological concept of this rare headache disorder characterised by a distinct, clearly remembered onset and its instant chronification. Method: Magnetic resonance-based voxel-based and surface-based morphometry was used to investigate 23 patients suffering from new daily persistent headache and 23 age- and gender-matched healthy controls with 1.5 Tesla MRI. Independent statistical analysis was performed at three sites using statistical parametric mapping, as well as FSL(FMRIB Software Library)-based approaches. Results: No grey matter changes were detected using this sophisticated and cross-checked method. Conclusion: The absence of structural brain changes in patients with new daily persistent headache contribute to the recent discussion regarding structural alterations in primary headache disorders in general and does not provide evidence for grey matter changes being associated with the pathophysiology of new daily persistent headache. Future research will have to determine the underlying pathophysiological mechanisms of this disorder.
- Open Access
The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
Mitochondrial processes may play a role in the pathophysiology of migraine. Serum levels of two biomarkers, Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15), are typically elevated in patients with mitochondrial disorders. The study investigated whether the presence of migraine may influence FGF-21 and GDF-15 serum levels considering vascular and metabolic disorders as possible confounders. A cross-sectional study in two headache centers was conducted analyzing GDF-15 and FGF-21 serum concentration in 230 patients with episodic and chronic migraine compared to a control group. Key clinical features of headache were evaluated, as well as health-related life quality, anxiety and depression using SF-12 and HADS-questionnaires. Elevated GDF-15 values were detected in the migraine group compared to the control group (506.65 ± 275.87 pg/mL vs. 403.34 ± 173.29 pg/mL, p < 0.001, Mann–Whitney U test). A strong correlation between increasing age and higher GDF-15 levels was identified (p < 0.001, 95%-CI elevation of GDF-15 per year 5.246–10.850 pg/mL, multiple linear regression). Mean age was different between the groups, and this represents a confounding factor of the measurements. FGF-21 levels did not differ between migraine patients and controls (p = 0.635, Mann–Whitney U test) but were significantly influenced by increasing BMI (p = 0.030, multiple linear regression). Neither biomarker showed correlation with headache frequency. Higher FGF-21 levels were associated with a higher mean intensity of headache attacks, reduced health-related life quality and anxiety. When confounding factors were considered, increased serum levels of FGF-21 and GDF-15 were not detected in migraine patients. However, the results show an age-dependence of GDF-15 in migraine patients, and this should be considered in future studies. Similar findings apply to the relationship between FGF-21 and BMI. Previous studies that did not adjust for these factors should be interpreted with caution.
Open AccessThe Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine
Mitochondrial processes may play a role in the pathophysiology of migraine. Serum levels of two biomarkers, Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15), are typically elevated in patients with mitochondrial disorders. The study investigated whether the presence of migraine may influence FGF-21 and GDF-15 serum levels considering vascular and metabolic disorders as possible confounders. A cross-sectional study in two headache centers was conducted analyzing GDF-15 and FGF-21 serum concentration in 230 patients with episodic and chronic migraine compared to a control group. Key clinical features of headache were evaluated, as well as health-related life quality, anxiety and depression using SF-12 and HADS-questionnaires. Elevated GDF-15 values were detected in the migraine group compared to the control group (506.65 ± 275.87 pg/mL vs. 403.34 ± 173.29 pg/mL, p < 0.001, Mann–Whitney U test). A strong correlation between increasing age and higher GDF-15 levels was identified (p < 0.001, 95%-CI elevation of GDF-15 per year 5.246–10.850 pg/mL, multiple linear regression). Mean age was different between the groups, and this represents a confounding factor of the measurements. FGF-21 levels did not differ between migraine patients and controls (p = 0.635, Mann–Whitney U test) but were significantly influenced by increasing BMI (p = 0.030, multiple linear regression). Neither biomarker showed correlation with headache frequency. Higher FGF-21 levels were associated with a higher mean intensity of headache attacks, reduced health-related life quality and anxiety. When confounding factors were considered, increased serum levels of FGF-21 and GDF-15 were not detected in migraine patients. However, the results show an age-dependence of GDF-15 in migraine patients, and this should be considered in future studies. Similar findings apply to the relationship between FGF-21 and BMI. Previous studies that did not adjust for these factors should be interpreted with caution.